Author: PharmaSignal News Desk

Tecvayli multiple myeloma data presented at ASH suggests potential for early use in treatment, involving 165 patients.

Tern leukemia drug shows potential at ASH Conference, challenging Novartis’ Scemblix with promising early results.

Mirum Bluejay acquisition secures a late-stage hepatitis D drug, enhancing its pipeline with potential $200M in additional payouts.

Dyne Duchenne drug approval could challenge Sarepta’s Exondys 51, impacting the market and offering new clinical insights.

Lilly Jaypirca trial demonstrates efficacy comparable to Imbruvica with safety advantages, potentially altering leukemia and lymphoma treatment.

Vertex CRISPR therapy demonstrates early success in children with sickle cell and thalassemia, potentially expanding its market reach.

ACIP vaccine schedule is under review by a panel, following changes to the hepatitis B vaccine endorsement.

Hemophilia gene therapy faces market challenges despite innovation, with BioMarin, CSL, and Pfizer navigating barriers.

Praxis shares rise 40% following positive updates on two drugs, while Bristol Myers’ Breyanzi gains approval for a fifth cancer indication.

CDC panel delays vote on hepatitis B vaccine for newborns, impacting public health.

• CDC panel delays decision on hepatitis B vaccine.
• Vote affects millions of newborns annually.
• Public health implications are significant.